GlassScriptPhysician profile
Ena Sharma
NPI 1235577941
$13,188.08
in general payments reported to CMS, 2019-2025
28 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,973 · 2020: $615 · 2021: $710 · 2022: $864 · 2023: $4,549 · 2024: $770 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,230 · Food and Beverage: $1,733 · Education: $63.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,229.75 |
| Food and Beverage | $1,733.49 |
| Education | $63.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,945.78 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $1,923.25 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $1,489.10 | 2019-2025 | |
| Pfizer INC. | $301.87 | 2019-2021 | |
| Horizon Therapeutics Plc | $294.17 | 2019-2020 | |
| Lilly USA, LLC | $248.49 | 2019-2022 | |
| Genentech USA, INC. | $236.33 | 2019-2020 | |
| Genzyme Corporation | $216.76 | 2019 | |
| Celgene Corporation | $208.58 | 2019 | |
| Mallinckrodt Enterprises LLC | $168.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.60 | 2019 | |
| Ucb, INC. | $136.34 | 2019-2024 | Bimzelx |
| Radius Health, INC. | $130.02 | 2019-2023 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $120.13 | 2022 | |
| Janssen Biotech, INC. | $113.37 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $94.61 | 2019 | |
| Depuy Synthes Sales INC. | $87.08 | 2019 | |
| Mallinckrodt Hospital Products INC. | $51.80 | 2020 | |
| Alexion Pharmaceuticals, INC. | $46.78 | 2019 | |
| Medexus Pharma, INC. | $39.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.83 | 2020 | |
| Glaxosmithkline, LLC. | $28.00 | 2019-2020 | |
| Tesaro, INC. | $25.88 | 2019 | |
| Bioventus LLC | $24.91 | 2020 | |
| Amag Pharmaceuticals, INC. | $23.91 | 2019 | |
| Blueprint Medicines Corporation | $20.32 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.68 | 2019 | |
| Agios Pharmaceuticals, INC. | $16.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ena Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.